The International Society of DNA Vaccines

Dr. Ulmer received his B.Sc. from the Department of Chemistry at the University of Regina and received his Ph.D. in Biochemistry from McGill University. Postdoctoral training was completed in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. Currently Head, Immunology & Cell Biology at Novartis Vaccines and Diagnostics, his group is responsible for discovery and technology development of vaccines and adjuvants.

Dr. Jeff Ulmer
Senior Director, Vaccines Research
Novartis Corporation 

 

 
Britta Wahren
Microbiology and Tumorbiology Center
Karolinska Institute and Swedish Institute for Infectious Disease Control 

 

 
Professor Stevenson has a DPhil degree from the University of Oxford. Her continuing interest is in strategies to target the immune response against malignant cells by vaccination. The tumor target has been B cell-lymphoma with a focus on the immunoglobulin expressed specifically by tumor cells. The vaccine design is based on DNA sequences encoding the target molecule with delivery of the plasmid DNA vaccine directly into the patient.

  
Freda Stevenson
Tenovus Laboratory University of Southampton 

  
After graduating with a B.S. degree in Chemistry/Mathematics from Wofford College, Dr. Shiver received a Ph.D. in Physical Chemistry from the University of Florida and completed a postdoctoral fellowship in Biophysics at Purdue University. Following his time with the National Cancer Institute at NIH, Dr. Shiver now serves as Vice President, Worldwide Basic Research Franchise Head, of Vaccines at Merck.

 

Dr. John Shiver
Vice President, Vaccine and Biologics Research
Merck and Co., Inc.

 

Dr. Shan Lu is a Professor of Medicine at the University of Massachusetts Medical School. He is a well-known expert on novel human vaccine development against a wide range of major human pathogens. He has designed a novel candidate human HIV vaccinew hich showed promising immune responses in a recently completed phase I clinical trial. He has received research funding from the NIH to find safer vaccines for protection against diseases such as smallpox, plague and anthrax.

 

Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, and Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer, Sanofi Pasteur, where for seven years he was Medical and Scientific Director. He developed the rubella vaccine now in standard use throughout the world, and has worked extensively on the development and application of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus.